Overview
This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions [smoldering MM (SMM) and monoclonal gammopathy of undetermined significance (MGUS)], Hodgkin lymphoma (HL), non-Hodgkin aggressive lymphoma NHL [diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), Marginal Zone Lymphoma (MZL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and subjects at risk and control subjects with no malignant disease.
Description
Subjects will be screened for eligibility and then, after signing an Informed Consent Form, the first peripheral blood sample will be obtained.
Periodical blood samples will be obtained from the participants. Relapse patients will have their retrospective blood samples analyzed to identify early signs of disease.
The first stage (discovery phase) will include at least 30 patients from each of the following groups: MM, pre-MM conditions (SMM and MGUS), HL, aggressive NHL (DLBCL, HGL, FL, and MZL transformed to large cell lymphoma), FL, MZL, AML, MDS, and control subjects with no malignant disease.
In the second stage, at least 250 patients with MM and 250 patients with NHL, and at least 100 patients with each of the remaining hematological malignancies mentioned above will be tested. Out of these patients, AML, lymphoma and MM patients will be followed-up at the clinical sites. Periodic sampling will be defined according to disease type and progression rate. Blood and plasma samples will be stored in the clinical sites until relapse diagnosis. At this stage, blood samples will be analyzed retrospectively on the HemaChip. The screening, enrollment and blood collection can begin in the first stage of the trial, in order to allow a maximum follow-up period for at-risk subjects as part of the study and to meet the recruitment goals.
The last stage consists of the screening of a larger group of subjects with a high risk of blood cancer. This stage will include three populations: up to 1000 follow-up patients from each blood cancer: AML, lymphoma, and MM, up to 600 elderly patients (>65 years old) at risk of developing MM, and up to 400 first-degree relatives of patients (and in particular siblings). In order to allow a maximum follow-up period for at-risk subjects as part of the study, and to meet the recruitment goals, the screening, and enrollment can begin in the first stage of the trial.
The last stage consists of screening a larger group of subjects at risk of developing MM / lymphoproliferative disorder. This stage will include 400 elderly patients (>65 years old) and 500 first-degree relatives of patients (and in particular siblings). The screening, enrollment, and sample collection can begin in the first stage of the trial, in order to allow a maximum follow-up period for at-risk subjects as part of the study and to meet the recruitment goals.
In all stages, the age and sex-matched subgroups will be considered and matched.
During the follow-up period, demographic and baseline parameters including sex, age, race, height and weight, medical history, smoking status, details of initial diagnosis and treatment history, concomitant medications as well as adverse events (AEs) of special interest (see section 9.1), (serious) AEs related to study procedures, treatment for the disease, disease response and survival status will be collected (as applicable).
Eligibility
Inclusion Criteria:
General criteria for all study populations:
- Male and female subjects ≥18 years of age
- Ability to understand and willingness to sign a written informed consent document.
For Patients with hematological malignancies:
- Patients who have been diagnosed, have measurable disease and/or are being monitored/followed up due to one of the following conditions: MM, pre-MM conditions (SMM and MGUS), HL, aggressive NHL (DLBCL), FL, MZL, AML, MDS that did not yet undergo any treatment.
NOTE: Patients diagnosed with DLBCL that is transformed from FL or MZL, and patients
diagnosed with AML secondary to MDS or MPN, that were treated for their primary disease
(FL/MZL/MDS/MPN) prior to study enrollment, are eligible.
For subjects at risk for developing the investigated hematological malignancies:
1. First-degree relatives;
2. Elderly subjects ≥ 65 years of age.
Exclusion Criteria:
1. Patients/subjects with current co-diagnosis of another type of cancer;
2. Patients/subjects with a known active or prior cancer (other than defined as study
population), occurring within the last 2 years (even if considered to be in complete
remission). Patients/subjects with non-melanoma skin cancer or carcinoma in situ of
any type are not excluded if they have undergone complete resection;
3. Patients/subjects with active inflammatory autoimmune disease that requires treatment
with immunosuppressive/ immunomodulation agents;
4. Patients/subjects with known human immunodeficiency virus (HIV) positive;
5. Patients/subjects with known active Hepatitis A/B/C or past hepatitis C;
6. Subjects that are likely to be noncompliant with the protocol, or felt to be
unsuitable by the investigator for any other reason.